GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IN8bio Inc (NAS:INAB) » Definitions » EBIT

INAB (IN8bio) EBIT : $-31.30 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is IN8bio EBIT?

IN8bio's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-6.04 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-31.30 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. IN8bio's annualized ROC % for the quarter that ended in Sep. 2024 was -202.51%. IN8bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -260.81%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. IN8bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -138.91%.


IN8bio EBIT Historical Data

The historical data trend for IN8bio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IN8bio EBIT Chart

IN8bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -5.07 -8.56 -14.65 -28.52 -30.34

IN8bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.17 -7.93 -8.65 -8.69 -6.04

Competitive Comparison of IN8bio's EBIT

For the Biotechnology subindustry, IN8bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IN8bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where IN8bio's EV-to-EBIT falls into.



IN8bio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IN8bio  (NAS:INAB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

IN8bio's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-24.164 * ( 1 - 0% )/( (12.625 + 11.24)/ 2 )
=-24.164/11.9325
=-202.51 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

IN8bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-24.164/( ( (9.235 + max(-0.512, 0)) + (8.499 + max(0.796, 0)) )/ 2 )
=-24.164/( ( 9.235 + 9.295 )/ 2 )
=-24.164/9.265
=-260.81 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.465) - (1.948 + 0 + 1.029)
=-0.512

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.702) - (1.658 + 0 + 0.248)
=0.796

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

IN8bio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-31.303/22.535
=-138.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IN8bio EBIT Related Terms

Thank you for viewing the detailed overview of IN8bio's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


IN8bio Business Description

Traded in Other Exchanges
Address
350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Executives
Jeremy R. Graff director C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Patrick Mccall officer: Chief Financial Officer C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
William Tai-wei Ho director, officer: President, CEO and CFO C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Fund Ii, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Leslie W. Kreis director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Fletcher Aaron G.l. director, 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Transcend Partners Opportunity Fund Llc 10 percent owner 10 ORINDA VIEW ROAD, ORINDA CA 94563
Lawrence Lamb officer: EVP and CSO C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Incysus Co-invest I, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Trishna Goswami officer: Chief Medical Officer C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Kate Rochlin officer: Chief Operating Officer IN8BIO, INC., EMPIRE STATE BUILDING, SUITE 5330, NEW YORK NY 10118